share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

SEC announcement ·  Mar 6 06:45
Summary by Futu AI
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.